https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-05-30 / J. Immunol. Methods 2012 Aug;382(1-2):1-23
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-05-30 / J. Immunol. Methods 2012 Aug;382(1-2):1-232012-05-30 00:00:002019-02-15 08:39:55Cancer therapy and vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-05-29 / Appl. Biochem. Biotechnol. 2012 Aug;167(7):2005-22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-05-29 / Appl. Biochem. Biotechnol. 2012 Aug;167(7):2005-222012-05-29 00:00:002019-02-15 09:21:30Velogenic newcastle disease virus as an oncolytic virotherapeutics: in vitro characterization
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-05-29 / Nat Rev Urol 2012 May;9(7):376-85
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-05-29 / Nat Rev Urol 2012 May;9(7):376-852012-05-29 00:00:002019-02-15 08:53:11Cancer immunotherapy: a paradigm shift for prostate cancer treatment
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-05-05 / Case Rep Oncol 2012 May;5(2):212-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-05-05 / Case Rep Oncol 2012 May;5(2):212-52012-05-05 00:00:002019-02-15 08:48:33Successful treatment of advanced ovarian cancer with thermochemotherapy and adjuvant immune therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-05-01 / Curr Opin Urol 2012 May;22(3):197-202
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-05-01 / Curr Opin Urol 2012 May;22(3):197-2022012-05-01 00:00:002019-02-15 09:23:55Current status of immunological approaches for the treatment of prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-05-01 / J. Cell. Biochem. 2012 May;113(5):1547-58
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-05-01 / J. Cell. Biochem. 2012 May;113(5):1547-582012-05-01 00:00:002019-02-15 08:39:18Hyperthermia-enhanced TRAIL- and mapatumumab-induced apoptotic death is mediated through mitochondria in human colon cancer cells